In T2DM patients at high risk of developing cardiovascular diseases, empagliflozin treatment can diminish NLRP3 inflammasome activation and secretion of IL-1β in isolated human macrophages after stimulation with LPS and Adenosine triphosphate (ATP) or palmitate, which could be one of the mechanisms that contribute to the proven empagliflozin ́s cardioprotective effects [230]. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.